Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
Start Date
3/23/2026
Completion Date
11/27/2027
Summary
This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate: 1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to baseline due to GGC supplementation. 2. To study the changes in motor function, cognitive skills in PD patients due to GGC oral supplementation 3. To study impact of GGC on gut health on the PD patients.
Detailed Description
This study will measure brain glutathione using non- invasive, state-of-the-art MEGA-PRESS pulse sequence in pre and post GGC supplementation after 12 months. The GSH level will also be measured in the blood in pre and post GGC supplementation. Brain and blood iron level will be measured in pre and post GGC supplementation. The neuropsychological examination and motor function will be performed in pre and post GGC supplementation. This study will provide the relation of brain GSH enrichment with motor performance. Our study will also provide any possible correlation with reduction of dysbiosis of the gut microbiome with GSH enrichment.
Eligibility Criteria
Age Range: 50 years to 80 years
Interventions
Gamma- glutamylcysteine
Conditions
Locations
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania 15213
United States